Management of Wet Age-Related Macular Degeneration in Spain: Challenges for Treat and Extend Implementation in Routine Clinical Practice
Table 1
Panelists opinion (n = 49) regarding anti-VEGF treatment strategies considered as optimal for wAMD management according to patient profile and lesion type in Spain.
PRN strict
PRN flexible
Fixed dose
T&E strict
T&E flexible
No treatment
Patient characteristics; opinion, n (%)
Very low initial VA
12 (24%)
6 (12%)
3 (6%)
25 (51%)
7 (14%)
6 (12%)
Good initial VA
10 (20%)
1 (2%)
9 (18%)
34 (69%)
3 (6%)
0 (0%)
Aged patient
7 (14%)
2 (4%)
9 (18%)
24 (49%)
13 (27%)
1 (2%)
Single eye
14 (29%)
0 (0%)
11 (22%)
34 (69%)
1 (2%)
0 (0%)
Adverse events risk
16 (33%)
9 (18%)
1 (2%)
12 (24%)
10 (20%)
2 (4%)
Centre accessibility (distance)
4 (8%)
4 (8%)
7 (14%)
26 (53%)
10 (20%)
0 (0%)
Protocol/centre guidelines
12 (24%)
3 (6%)
8 (16%)
27 (55%)
10 (20%)
0 (0%)
Patient cost
13 (27%)
10 (20%)
4 (8%)
15 (31%)
11 (22%)
1 (2%)
Disease characteristics (type of lesion); opinion, n (%)
